Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05494788 · ClinicalTrials.gov registry record · Phase 2
Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)
A Phase 2 study, sponsored by Cardiol Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT05494788 is a Phase 2 study that has completed, run by Cardiol Therapeutics. The registered enrollment target is 27 participants.
The verdict
NCT05494788, a Phase 2 study, has completed, sponsored by Cardiol Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
Patients with recurrent pericarditis who are refractory or intolerant to current therapeutic management options or who require long-term administration of corticosteroids to control their disease are particularly challenging to manage. The pathogenesis of pericarditis involves the activation of the inflammasome. CardiolRxTM (a pure cannabidiol \[CBD\] solution) is known to have anti-inflammatory properties, including modulation of inflammasome signaling. This pilot study is to assess the tolerance and safety of CardiolRxTM during the resolution of pericarditis symptoms, assess improvement in objective measures of disease, and during the extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids while taking CardiolRxTM.
Interventions
- DRUG CardiolRx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2023-01-09 |
| Est. Completion | 2024-09-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05494788
The ClinicalTrials.gov registry entry for NCT05494788 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cardiol Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CardiolRx is the first listed.
NCT05494788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05494788 about?
NCT05494788 is a clinical study titled "Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)". Patients with recurrent pericarditis who are refractory or intolerant to current therapeutic management options or who require long-term administration of corticosteroids to control their disease are particularly challenging to manage. The pathogenesis of pericarditis involves the activation of the ...
What is the current status of trial NCT05494788?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2023-01-09. Estimated completion is 2024-09-06.
What interventions are being tested in trial NCT05494788?
The interventions under investigation include: CardiolRx (DRUG).
Who is sponsoring clinical trial NCT05494788?
This trial is sponsored by Cardiol Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.